Valneva SE

Valneva Reports Positive 24-Month Antibody Persistence Data for its Single-Shot Chikungunya Vaccine IXCHIQ®

04 12月 2023 01:00:00 条件 Nasdaq GlobeNewswire

EMA Accepts Valneva’s Chikungunya Vaccine Marketing Authorization Application for Accelerated Assessment

27 11月 2023 01:00:00 条件 Nasdaq GlobeNewswire

Valneva Announces the Availability of Documentation for its Extraordinary General Meeting including Planned Changes to its Future Board of Directors

15 11月 2023 01:30:00 条件 Nasdaq GlobeNewswire

Valneva Announces U.S. FDA Approval of World’s First Chikungunya Vaccine, IXCHIQ®

10 11月 2023 01:00:00 条件 Nasdaq GlobeNewswire

Valneva Reports Nine-Month 2023 Financial Results and Provides Corporate Updates

09 11月 2023 01:00:00 条件 Nasdaq GlobeNewswire

Valneva to Present and Hold Investor Meetings at the Jefferies London Healthcare Conference

07 11月 2023 01:00:00 条件 Nasdaq GlobeNewswire

VALNEVA Declaration of shares and voting rights: October 31, 2023

06 11月 2023 02:30:00 条件 Nasdaq GlobeNewswire

Valneva Submits Chikungunya Vaccine Marketing Application to EMA and Announces CHMP Accelerated Assessment

25 10月 2023 12:15:00 条件 Nasdaq GlobeNewswire

Valneva to Present on Chikungunya at Several Leading Scientific Conferences

11 10月 2023 11:45:00 条件 Nasdaq GlobeNewswire

VALNEVA - Declaration of shares and voting rights: September 30, 2023

05 10月 2023 02:30:00 条件 Nasdaq GlobeNewswire

Valneva Announces New IXIARO® Supply Contract with the U.S. Government Worth a Minimum of $32 Million

25 9月 2023 01:00:00 条件 Nasdaq GlobeNewswire

Valneva Reports Half Year 2023 Financial Results and Provides Corporate Updates

21 9月 2023 01:00:00 条件 Nasdaq GlobeNewswire

Valneva and Pfizer Report Positive Pediatric and Adolescent Phase 2 Booster Results for Lyme Disease Vaccine Candidate

07 9月 2023 01:00:00 条件 Nasdaq GlobeNewswire

VALNEVA Declaration of shares and voting rights: August 31, 2023

06 9月 2023 02:30:00 条件 Nasdaq GlobeNewswire

Valneva to Participate in Investor Conferences in the United States and Europe in September 2023

31 8月 2023 13:00:00 条件 Nasdaq GlobeNewswire

Health Canada Accepts Valneva’s Chikungunya Vaccine License Application for Review

29 8月 2023 01:00:00 条件 Nasdaq GlobeNewswire

Valneva Reports Positive Initial Phase 3 Safety Data in Adolescents for its Single-Shot Chikungunya Vaccine Candidate

28 8月 2023 01:00:00 条件 Nasdaq GlobeNewswire

Valneva Announces Extension of Existing Loan Agreement

17 8月 2023 01:00:00 条件 Nasdaq GlobeNewswire

Valneva Announces PDUFA Date Extension for Chikungunya Virus Vaccine Candidate

14 8月 2023 01:00:00 条件 Nasdaq GlobeNewswire

VALNEVA Declaration of shares and voting rights - July 31, 2023

03 8月 2023 02:30:00 条件 Nasdaq GlobeNewswire